Surgical Outcome of Macular Membrane Peeling Associated With Significant Macular Drusen
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Surgical outcome of patients with macular drusen and co-existing abnormalities of the vitreoretinal interface, who routinely undergo pars plana vitrectomy with membrane peeling, is evaluated. Best corrected visual acuity as well as optical coherence tomography data are compared at baseline and last follow up. The rate of development of choroidal neovascularization postoperatively is noted.
Condition or disease
Epiretinal MembraneMacular HolesAge Related Macular Degeneration
Procedure: pars plana vitrectomy with membrane peeling
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
mostly elderly people, mean age 66 years, both males and females
participants diagnosed with ERM or FTMH and co-existing macular drusen;
undergone pars plana vitrectomy with ILM and epiretinale membrane peeling;
SD-OCT at the initial visit and at last follow up visit with image quality score >30;
no evidence of CNV on initial fluorescein angiography (FA).
history of other macular disease, severe non-proliferative or proliferative diabetic retinopathy, other retinal vascular diseases, glaucoma, myopic retinopathy, or other diseases interfering with OCT images in any one of the eyes;